- Home
- FINS vs NMRA Comparison
FINS vs NMRA Comparison
Compare FINS & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FINS | NMRA |
|---|---|---|
| Founded | 2019 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.1M | 424.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | FINS | NMRA |
|---|---|---|
| Price | $12.99 | $1.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 78.0K | ★ 984.8K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 9.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.61 | $0.61 |
| 52 Week High | $12.57 | $11.57 |
Technical Indicators
Market Signals| Indicator | FINS | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 31.12 |
| Support Level | $12.99 | $2.05 |
| Resistance Level | $13.17 | $2.36 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 7.14 | 0.62 |
Price Performance
Historical ComparisonAbout FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.